I think it's unlikely but if it happens at all it will be before the ASCO abstracts are released; after that there are a string of potential positive catalysts to consider:
Ponatinib partnering in Asia and/or EU Start AP113 Phase 1 trial New Phase 3 ridaforolimus trials ASCO First look at ponatinib data at ASH? Ponatinib full enrollment Filing rida NDA
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.